Literature DB >> 2568906

Characteristics of warfarin hydroxylation catalyzed by human liver microsomes.

A E Rettie1, A C Eddy, L D Heimark, M Gibaldi, W F Trager.   

Abstract

The oxidative biotransformation of (R)- and (S)-warfarin was studied in human liver microsomes to determine whether an in vitro model could be established that would correspond to the in vivo profile that is generally observed. The quantitative pattern of oxidized products obtained from warfarin in vitro changed dramatically as a function of substrate concentration. Apparent Km values for the formation of 4', 6, 7, and 8-hydroxywarfarin indicated the presence of two easily distinguishable subsets of human liver cytochrome P-450; a high affinity subset (Km 3-15 microM) and a low affinity subset of isozymes (Km greater than 200 microM). The high affinity subset is primarily responsible for the metabolic profile of the biologically more potent (S)-enantiomer in vivo, whereas the low affinity subset is largely responsible for metabolism of the (R)-enantiomer. Apparent Vmax values alone did not reflect the relative in vivo formation clearances of the phenolic metabolites from either antipode, because the low affinity-high capacity component masked the metabolic profile of the (S)-enantiomer. However, the rank order of intrinsic clearance, Vmax/Km, for each metabolite was in good agreement with regio- and stereoselective metabolism in vivo. This investigation highlights the need for rigorous kinetic characterization of an in vitro model before reasonable correlation can be expected with in vivo data.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568906

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

1.  Pregnancy decreases rat CYP1A2 activity and expression.

Authors:  Alysa A Walker; Leslie Dickmann; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2010-10-04       Impact factor: 3.922

Review 2.  Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.

Authors:  P Glue; C R Banfield; J L Perhach; G G Mather; J K Racha; R H Levy
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

Review 3.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Human and mouse liver coumarin 7-hydroxylases do not metabolize warfarin in vitro.

Authors:  P Honkakoski; P Arvela; R Juvonen; M A Lang; M Kairaluoma; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 5.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

6.  The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype.

Authors:  John Maddison; Andrew A Somogyi; Berit P Jensen; Heather M James; Melanie Gentgall; Paul E Rolan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

7.  Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid.

Authors:  O Spiegelstein; D L Kroetz; R H Levy; B Yagen; S I Hurst; M Levi; A Haj-Yehia; M Bialer
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

8.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

9.  Quantum mechanics/molecular mechanics modeling of regioselectivity of drug metabolism in cytochrome P450 2C9.

Authors:  Richard Lonsdale; Kerensa T Houghton; Jolanta Żurek; Christine M Bathelt; Nicolas Foloppe; Marcel J de Groot; Jeremy N Harvey; Adrian J Mulholland
Journal:  J Am Chem Soc       Date:  2013-05-16       Impact factor: 15.419

10.  Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.

Authors:  Arinao Ndadza; Sarudzai Muyambo; Pindile Mntla; Ambroise Wonkam; Emile Chimusa; Andre P Kengne; Mpiko Ntsekhe; Collet Dandara
Journal:  J Thromb Haemost       Date:  2021-09-29       Impact factor: 16.036

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.